KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBITDA (2016 - 2026)

Medpace Holdings filings provide 12 years of EBITDA readings, the most recent being $148.3 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 23.32% to $148.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $590.2 million, a 21.89% increase, with the full-year FY2025 number at $562.1 million, up 18.43% from a year prior.
  • EBITDA hit $148.3 million in Q1 2026 for Medpace Holdings, down from $160.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $160.2 million in Q4 2025 to a low of $64.9 million in Q2 2022.
  • Median EBITDA over the past 5 years was $110.7 million (2024), compared with a mean of $108.5 million.
  • Biggest five-year swings in EBITDA: surged 43.29% in 2022 and later increased 8.6% in 2025.
  • Medpace Holdings' EBITDA stood at $81.5 million in 2022, then increased by 15.03% to $93.7 million in 2023, then soared by 41.36% to $132.5 million in 2024, then increased by 20.88% to $160.2 million in 2025, then dropped by 7.45% to $148.3 million in 2026.
  • The last three reported values for EBITDA were $148.3 million (Q1 2026), $160.2 million (Q4 2025), and $148.6 million (Q3 2025) per Business Quant data.